87 results about "Benign hemangiomas" patented technology

The present invention discloses an anti-tumor compound and its preparation method,application, and pharmaceutical compositions. The anti-tumor compound is a 4 - nitro-substituted benzyl group ifosfamide ester prodrug thereof, or pharmaceuticallysalt, or solvate thereof of the structure of formula I. The structure of formula I. The present invention has the following advantage of being used for the treatment or prevention of mammalian tumor-related diseases, such as leukemia, hemangioma, glioma, Kaposi's sarcoma, ovarian cancer, breast cancer, lung cancer, pancreatic cancer, lymphoma, prostate, colon and skin tumors and their complications.

The invention discloses a retina hemangioma image segmentation method based on a GAN (Generative Adversarial Network), and the method comprises the steps: constructing a GAN structure, wherein the GANstructure comprises a generator and a discriminator, the generator comprises a plurality of downsampling layers and an equal number of upsampling layers, and the discriminator comprises a plurality of downsampling layers; taking a hemangioma artificial segmented image and an original fundus retina image as training data, performing iterative training of the GAN, and obtaining an optimal generator; performing hemangioma image segmentation of a to-be-segmented fundus retina image based on the optimal generator. Compared with a conventional retina hemangioma image segmentation method based on animage processing algorithm, the method can achieve the more accurate and clear segmentation of the image, reduces a false positive segmentation result, and is more precise in image segmentation details.

The invention belongs to the technical field of medicines, and provides a propranolol hydrochloride (PPL.HCL) gel which can be externally used for treating infant superficial hemangioma. The propranolol hydrochloride gel is mainly prepared from propranolol hydrochloride, gel matrix, a percutaneous penetration enhancer, a preservative, a humectant and the like. By using the propranolol hydrochloride gel, adverse reactions such as decreased heart rate, cyanosis, airway hyperresponsiveness, shortage of granular leukocytes, diarrhoea, sleep change and blood sugar reduction caused by orally taking propranolol by hemangioma patients can be reduced and even avoided, and the problems that oral dosage is not easy to control, infants inconveniently take medicines and the like are solved.

The invention provides the application of tetracyclic triterpenoids compound cucurbitacins E in preparing anti-angiogenic drugs. The cucurbitacins E can inhibit tumor angiogenesis, arthritis pathological tissue vessel angiogenesis, neovascular eye disease, hemangioma pathological tissue angiogenesis, psoriasis pathological tissue vessel angiogenesis, solid tumor pathological tissue angiogenesis, hemangioma, Kaposi' s sarcoma pathological tissue angiogenesis, leukocythemia, lymphadenoma, myeloma blood cancer and Paget' s disease angiogenesis. The invention also provides the application of a compound containing effective dose of cucurbitacins E and pharmacy acceptable ingredients in preparing the anti-angiogenic drugs.

The invention relates to the field of medicines, and in particular relates to an inhibitor of angiogenesis capable of inhibiting matrix metallo-proteinase and migration of vascular endothelial cells. The inhibitor can be used for preventing and treating solid tumor and rheumatoid arthritis. The polypeptide specifically means polypeptide I, polypeptide II, polypeptide III and polypeptide IV (with reference to SeqNO.1, SeqNO.2, SeqNO.3 and SeqNO.4). The polypeptide can be used for treating solid tumor and rheumatoid arthritis. The four inhibitors of angiogenesis can be applied to preparing medicines for treating tumor. The polypeptide is characterized in that tumor is originated from essential or subsequent cancers, melanoma, hemangioma and sarcoma of heat and neck, brain, thyroid, esophagus, pancreas, lung, liver, stomach, breast, kidney, gall bladder, colon or rectum, ovary, cervix uterus, uterus, prostate, bladder and testis.

This invention concerns a method of treating hemangiomas with a beta blocker by applying the beta blocker onto the hemangiomas directly. The invention also concerns a combination therapy by using a beta blocker along with a corticosteroid or an alpha adrenergic receptor agonist for the treatment of hemangiomas.

The invention provides an application of osthole in preparing anti-angiogenic drugs. The osthole can inhibit tumor angiogenesis, arthritis pathological tissue vessel angiogenesis, neovascular eye disease, hemangioma pathological tissue angiogenesis, psoriasis pathological tissue vessel angiogenesis, solid tumor pathological tissue angiogenesis, hemangioma, Kaposi's sarcoma pathological tissue angiogenesis, leukocythemia, lymphadenoma, myeloma blood cancer and Paget's disease angiogenesis. The invention also provides the application of a compound containing effective dose of osthole and pharmacy acceptable ingredients in preparing the anti-angiogenic drugs.

The present invention describes stem cells and progenitor cells derived from hemangiomas, including testing of angiogenic inhibitors using these cells. The invention as described is useful in providing a process to culture and propagate hemangioma stem cells and generate xenograft models to develop treatments for infantile hemangiomas and other types of vascular lesions.

The invention discloses a pingyangmycin polyethylene glycol (PEG)-polycaprolactone (PCL)-polyethylene glycol (PEG) temperature-sensitive slow-release gel, as well as a preparation method and the application of the gel. The Pingyangmycin PEG-PCL-PEG temperature-sensitive slow-release gel mainly consists of two parts comprising PEG (polyethylene glycol)-PCL (polycaprolactone)-PEG (polyethylene glycol) co-polymer and Pingyangmycin, is liquid at room temperature, and is solid gel under the in vivo 37 DEG C condition; the gel system has significant slow-release effect, thereby having functions in prolonging the half-life period and the acting time of the Pingyangmycin, reducing drug concentration in plasma, and reducing systemic toxic and side effects. The gel can be formed in situ after the medicine is injected in a high-flow-speed vessel, and then location embolism is realized, and so as to realize the, and muscularization and closing of muscle is caused, so that the sclerotherapy and the interventional therapy are combined effectively, the gel has excellent biocompatibility and degradability, is beneficial for treating hemangiomas, vascular malformations and cancers, particularly, a new selection is provided to the treatment of the vein malformation and partial malformation of cancers.

The invention relates to a decapeptide inhibiting angiogenesis and use thereof, belonging to the technical field of biological medicine. The decapeptide inhibiting angiogenesis provided by the invention is deprived from human Homo sapien with an amino acid sequence of YNWNSFGLRF and the molecular weight of 1303.4, and is named as Kp-10. The invention further provides use of the decapeptide inhibiting angiogenesis for preparing medicines for inhibition of angiogenesis, in particular relevant use of Kp-10 for preparing medicines for inhibition of angiogenesis dependent diseases such as cancer, rheumatoid arthritis, psoriasis, diabetes syndrome, and hemangioma. A series of experimental results in VEGF (Vascular Endothelial Growth Factor) induction shows that Kp-10 has obvious inhibition function in the proliferation experiment of human umbilical vein endothelial cells (HUVEC), transfer experiment, micro-tube forming experiment, angiogenesis experiment of chick embryo allantois and mouse cornea experiment, and the decapetide can be used for preparing medicines for inhibiting angiogenesis.

The invention provides a Chinese medicine composition capable of effectively treating cutaneous hemangioma, belonging to the field of Chinese medicines. the Chinese medicine composition for treating cutaneous hemangioma is characterized by being prepared from the Chinese medicinal herbs in parts by weight: 10 parts of astragalus mongholicus, 10 parts of rhizoma smilacis glabrae, 8 parts of dangshen, 12 parts of unprocessed rehmannia root, 15 parts of polygonum multiflorum, 20 parts of radices lithospermi, 12 parts of moutan bark, 15 parts of white paeony root, 8 parts of rhizoma corydalis, 5 parts of golden cypress, 5 parts of rhizoma anemarrhenae, 15 parts of Chinese thorowax root, 12 parts of radix curcumae, 12 parts of rhizoma sparganii, 10 parts of curcuma zedoary, 15 parts of calculus bovis and 20 parts of safflower carthamus. The Chinese medicine composition is prepared from the natural Chinese medicinal herbs as raw materials, is used for treating the cutaneous hemangioma by using combined action of all Chinese medicinal herbs, has no toxic and side effects to a human body, and has the advantages of low cost, capability of treating both principal and secondary aspect of the cutaneous hemangioma, and accurate treatment effect. Proved by 100 patients in clinical, the Chinese medicine composition for treating the cutaneous hemangioma has a cure rate of 96.0 percent, wherein 96 patients are cured and 4 patients get better.

The invention discloses a timolol external preparation for treating hemangioma. The prepared external preparation is ointment or gel prepared in the mode that two active ingredients including timolol and oleum menthae are added into a gel matrix or an ointment matrix, wherein the content of the timolol, by mass, accounts for 0.25-1% of the ointment or the gel, and the content of the oleum menthae, by mass, accounts for 1% of the ointment or the gel. The preparation method comprises the steps that timolol is prepared into a timolol saline solution in a salifying mode, the active ingredient oleum menthae is added into the timolol saline solution, the obtained solution is dispersed into the gel matrix according to the weight ratio of (1:1)-(1:10) to be subjected to swelling, and the gel is obtained; or the obtained solution is dispersed into the ointment matrix according to the weight ratio of (2.5:1)-(3:1), and the ointment is obtained. The preparation process is simple, easy to practice and applicable to requirements of industrial mass production. Pharmacodynamics results prove that the effective ingredients timolol and oleum menthae in the external preparation have the synergism for treating hemangioma and good tolerance, and no adverse reaction occurs.

The invention discloses an early warning system for ruptured artery hemangioma and an early warning method thereof. According to the invention, an ultrathin flexible sensor, ultrathin flexible temperature sensors and an ultrathin flexible strain sensor are implanted into the body through minimally invasive surgery; the strain sensor is wound and attached to the position of the hemangioma; the temperature sensors are wound and attached to the equidistant positions upstream and downstream the hemangioma; the early warning system has ultrahigh biological compatibility and will not cause internal rejection reaction; the sensors are directly and tightly attached to the measured positions and can be used for timely and accurately measuring the measured parameters; the ultrathin flexible characteristics of the sensors will not cause new focus by resulting in external damage to blood vessels and tissues; the signal is transmitted to a mobile terminal in the manner of near field communication; a microprocessor in the mobile terminal has an alarming function; when a deforming value or local blood pressure value of the hemangioma exceeds a threshold value, the microprocessor can alarm, so that the early warning system can conveniently monitor and measure early warning for a long time.

Methods for treating diseases or disorders of the skin which are characterized by angiogenesis have been developed using curcumin and curcumin analogs. Based on the results obtained with curcumin, it has been determined that other angiogenesis inhibitors can also be used to treat these skin disorders. It has further been discovered that curcumin acts to inhibit angiogenesis in part by inhibition of basic fibroblast growth factor (bFGF), and thereby provides a means for treating other disorders characterized by elevated levels of bFGF, such as bladder cancer, using curcumin and other analogues which also inhibit bFGF. Representative skin disorders to be treated include the malignant diseases angiosarcoma, hemangioendothelioma, basal cell carcinoma, squamous cell carcinoma, malignant melanoma and Karposi's sarcoma, and the non-malignant diseases or conditions including psoriasis, lymphangiogenesis, hemangioma of childhood, Sturge-Weber syndrome, verruca vulgaris, neurofibromatosis, tuberous sclerosis, pyogenic granulomas, recessive dystrophic epidermolysis bullosa, venous ulcers, acne, rosacea, eczema, molluscum contagious, seborrheic keratosis, and actinic keratosis.

The invention discloses a Chinese medicinal composition for treating a superficial tumor, which comprises the following components by mass: 10 to 30 grams of java brucea fruit; 10 to 30 grams of walnut kernel; 8 to 15 grams of unprocessed rhizoma pinelliae; 8 to 15 grams of common burreed rhizome; 3 to 8 grams of calomel; 3 to 8 grams of frankincense; 3 to 8 grams of myrrh; and 1 to 2 grams of polythrinicium. The medicinal composition is prepared by grinding the raw material medicaments respectively, uniformly mixing the powders and putting the powder into bottles. When the Chinese medicinal composition is used, the raw material medicaments are prepared into a paste by adding the right amount of white vinegar; and the paste is externally applied to affected parts of the tumor to block blood supply around the tumor to make the tumor die naturally. Clinical application shows that the Chinese medicinal composition has obvious curative effect on hemangioma, thyroidtumor and neurofibroma; a few scars are left after healing, but can be faded out gradually in the future; and the facial region is recovered well.

The invention discloses a traditional Chinese medicine preparation for cutaneous hemangioma and belongs to the invention field of traditional Chinese medicine. The traditional Chinese medicine preparation for cutaneous hemangioma comprises radix actinidiae chinensis, glabrous greenbrier rhizome, dandelion, olibanum, myrrh, radix paeoniae alba, spina gleditsiae, alga, kelp, rhizoma pinelliae, tangerine peels, prunella vulgaris, pericarpium citri reticulatae viride, atractylodes, cortex magnoliae officinalis, cortex dictamni, raw coix seeds, peach kernels, fructus polygoni orientalis, spreading hedyotis herbs, salvia chinensis, rhizoma paridis, rhizoma menipermi extracts, fructus psoraleae, fructus psoraleae, rhizoma sparganii and rhizoma curcumae. According to different characteristics of all the traditional Chinese medicine, all the raw materials are cleaned, cut into pieces, pretreated, blended in proportion and manufactured into the traditional Chinese medicine preparation for cutaneous hemangioma through the special method. The traditional Chinese medicine preparation for cutaneous hemangioma has the effects of activating blood to promote menstruation, promoting qi circulation, relieving pain, clearing heat, conducting detoxification, eliminating dampness and removing stasis. The combination and manufacturing method is unique; it is proved in clinical trials that the preparation for cutaneous hemangioma is remarkable in curative effect, short in treatment cycle and low in price, has no adverse effect and no toxic and side effect and has broad market application prospects.

The invention provides application of levo-propranolol in preparing a medicament for treating vasculopathy. During treatment of vasculopathy, particularly treatment of hemangioma, the treatment effectof the levo-propranolol is better than those of racemic propranolol and dextro-propranolol, and a good prospect is provided for the clinical treatment of hemangioma or infantile hemangioma.

The invention relates to a novel use of Chinese herbal medicine monomer embelin, in particular to an application of the embelin in a preparation of a drug for inhibiting angiogenesis. The embelin is applied in the inhibition of angiogenesis dependent disease such as mammary cancer, colon cancer, lymphoma, acute myelocytic leukemia, rheumatoidarthritis, psoriasis, diabetic syndrome, hemangioma, etc. Experiments show that the embelin has remarkable inhibitory action in proliferation experiment, migration experiment, invasion experiment, cell tabulation experiment, the angiogenesis of chick embryo allantois, etc. in the human microvascular endothelial cells (HMEC-1), thereby being used for preparing the drug for inhibiting the angiogenesis.

The present invention transplants hemangioma endothelial cell and tumor cell or tumor cell releasing product isolating cultured from human hemangioma structure, to immunologic deficiency mouse hypodermic, to obtain human hemangioma mouse animal model. The present invented technology method is portably in technical operation and with high model success ratio, the experimental evidence proving that said blood vessel endothelial cell in hemangioma model established is human hemangioma endothelial cell, and said model having the pathology property of human angiomatous intumescentia blood sinus and rebirth capillary vessel. Said hemangioma animal model can be used in system researching angiomatous pathogenesis screening human angiomatous therapeutic drug.

The invention discloses a method for automatically extracting and quantifying the color of a lesion area of an infantile hemangioma. The method comprises the steps of extracting a lesion part in an image of the infantile hemangioma, marking the lesion part as the lesion area and marking the remaining part as a skin area; converting color space of the lesion area and the skin area from red green blue (RGB) to international commission on illumination (CIE) Lab; extracting a mean value of chromatic values of three channels of the skin area to obtain a mean vector of the chromatic value of the skin area; extracting the mean value of chromatic values of three color channels of the lesion area to obtain the mean vector of the chromatic value of the lesion area; calculating distance by utilizingthe mean vector of the chromatic value of the skin area and the mean vector of the chromatic value of the lesion region, wherein the distance comprises Euclidean distance, Manhattan distance, Chebyshev distance, included angle cosine distance and related distance; and inputting the distance into an SVM (Support Vector Machine) classification model and outputting a classification result to realizeautomatic quantification of the color of the lesion area of the infantile hemangioma. Through the method disclosed by the invention, the automatic extraction and quantification of the color of the lesion area of the infantile hemangioma are realized.